免疫检查点抑制剂治疗后肾切除术的围手术期并发症与肿瘤学结局:多中心协作研究
该回顾性多中心研究纳入2011年1月至2021年9月美国五家学术中心113例接受免疫检查点抑制剂(ICI)治疗后行肾切除术的局部晚期或转移性肾细胞癌(RCC)患者,评估围手术期安全性与肿瘤学结局。结果显示90天并发症率为24%,12例(11%)需再入院;多因素分析中两个及以上危险因素(OR 2.91,95%CI 1.09-7.42)和病理T分期≥T3(OR 4.21,95%CI 1.13-15.8)与更高的90天并发症率独立相关。3年总生存率和无复发生存率分别为82%和47%。
要点
- ICI治疗后肾切除术的90天并发症率为24%,11%的患者需再入院。
- 两个及以上危险因素(OR 2.91)和病理T分期≥T3(OR 4.21)与90天并发症率升高独立相关。
- 3年总生存率和无复发生存率分别为82%和47%。
核心结论
- ICI治疗后行肾切除术是可行的,对于特定患者可作为一种潜在的巩固治疗选择。
- 作者认为新辅助治疗背景下也需进一步研究。
研究设计与样本
- 回顾性多中心协作研究,纳入2011年1月至2021年9月美国五家学术中心接受ICI治疗后行肾切除术的原发性局部晚期或转移性RCC患者113例,中位年龄63岁(IQR 56-69)。
主要发现
- 主要ICI方案为纳武利尤单抗±伊匹木单抗(n=85)和帕博利珠单抗±阿昔替尼(n=24)。
- 手术方式为109例根治性肾切除术和4例部分肾切除术,包括60例开放、38例机器人、14例腹腔镜,其中5例(10%)中转开放。
- 报告2例术中并发症(肠损伤和胰腺损伤)。
- 中位手术时间、估计失血量和住院时间分别为3小时、250 ml和3天。
- 6例(5%)达到完全病理缓解(ypT0N0)。
临床怎么用
- 作者认为对于特定患者,ICI治疗后肾切除术是可行的,可作为一种潜在的巩固治疗选择。
- 作者认为新辅助治疗背景下也需进一步研究。
局限性
- 研究为回顾性性质。
- 队列在临床病理特征和接受的ICI方案方面存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICIs) are now a mainstay of metastatic renal cell carcinoma (RCC) management with five current Food and Drug Administration-approved regimens. However, data regarding nephrectomy outcomes following an ICI are limited. OBJECTIVE: To evaluate the safety and outcomes of nephrectomy following an ICI. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review was performed of patients with primary locally advanced or metastatic RCC undergoing nephrectomy following an ICI in five US academic centers between January 2011 and September 2021. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Clinical data, perioperative outcomes, and 90-d complications/readmissions were recorded and evaluated by univariate and logistic regression models. Recurrence-free and overall survival probabilities were estimated by the Kaplan-Meier method. RESULTS AND LIMITATIONS: A total of 113 patients with a median (interquartile range) age of 63 (56-69) yr were included. The main ICI regimens were nivolumab ± ipilimumab (n = 85) and pembrolizumab ± axitinib (n = 24). Risk groups included 95% intermediate- and 5% poor-risk patients. Surgical procedures were 109 radical and four partial nephrectomies, including 60 open, 38 robotic, and 14 laparoscopic with five (10%) conversions. Two intraoperative complications were reported (bowel and pancreatic injury). The median operative time, estimated blood loss, and hospital stay were 3 h, 250 ml, and 3 d, respectively. A complete pathologic response (ypT0N0) was noted in six (5%) patients. The 90-d complication rate was 24%, with 12 (11%) patients requiring readmission. On a multivariable analysis, two or more risk factors (odds ratio [OR] 2.91, 95% confidence interval [CI]: 1.09, 7.42) and pathologic T stage ≥T3 (OR 4.21, 95% CI: 1.13-15.8) were independently associated with a higher 90-d complication rate. The 3-yr estimated overall survival and recurrence-free survival rates were 82% and 47%, respectively. Limitations include the retrospective nature and heterogeneous cohort in terms of clinicopathologic characteristics and ICI regimens received. CONCLUSIONS: Nephrectomy following ICI therapy is feasible and a potential consolidative therapy option in select patients. Further research in the neoadjuvant setting is also warranted. PATIENT SUMMARY: This study evaluates the outcomes of kidney surgery following immune checkpoint inhibitor therapy (mainly nivolumab and ipilimumab or pembrolizumab and axitinib) for patients with advanced kidney cancer. We utilized data from five academic centers across the USA and found that surgery in this setting did not have more complications or returns to the hospital than similar surgeries, indicating that it is a safe and feasible procedure at this time.
引用
- Yip W, Ghoreifi A, Gerald T, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. 2023. PMID: 37005212. doi:10.1016/j.euo.2023.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。